The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study): Short-term outcomes.
 
Maho Takayama
No Relationships to Disclose
 
Takamichi Ishii
No Relationships to Disclose
 
Masayuki Okuno
No Relationships to Disclose
 
Kiyoshi Hasegawa
No Relationships to Disclose
 
Mitsuo Shimada
No Relationships to Disclose
 
Susumu Eguchi
No Relationships to Disclose
 
Nobuyuki Takemura
No Relationships to Disclose
 
Akira Maki
No Relationships to Disclose
 
Itaru Endo
No Relationships to Disclose
 
Minoru Tanabe
No Relationships to Disclose
 
Yu Takahashi
No Relationships to Disclose
 
Tomoharu Yoshizumi
No Relationships to Disclose
 
Hideki Yokoo
No Relationships to Disclose
 
Yasuharu Sasaki
No Relationships to Disclose
 
Kohei Uemura
No Relationships to Disclose
 
Norihiro Kokudo
No Relationships to Disclose
 
Etsuro Hatano
Honoraria - Abbvie; AstraZeneca; Bayer; Chugai Pharma; Eisai; Incyte; Lilly; Merck; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Novartis; Shionogi
Research Funding - Eisai; Tsumura & Co.